BOULDER, Colo.--(BUSINESS WIRE)--The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of BioScrip, Inc. (“BioScrip” or the “Company”) (Nasdaq: BIOS). BioScrip is a New York-based company that provides home infusion and other home care services, and pharmacy benefit management services in the United States.
The Firm’s investigation relates to a U.S. Department of Justice Press Release which disclosed that BioScrip has agreed to forfeit $15 million for the Company’s participation in a kickback scheme with Novartis Pharmaceuticals, Inc. Following the public disclosure of these events, BioScrip stockholders filed a class action lawsuit against the Company in U.S. District Court Southern District of New York alleging that the Company had made false and misleading statements in its public Securities Exchange Commission (SEC) filings. On March 31, 2015, the federal judge denied, in part, the defendants’ motion to dismiss the complaint, and the case is proceeding towards trial.
If you currently own BioScrip common stock and are interested in discussing your rights, or have information relating to this investigation, please contact Kip B. Shuman or Rusty E. Glenn toll-free at (866) 569-4531 or email Mr. Shuman at kip@shumanlawfirm.com or email Mr. Glenn at rusty@shumanlawfirm.com.
The Shuman Law Firm represents investors throughout the nation, concentrating its practice in stockholder litigation.